

The in vitro and ex vivo antithrombotic properties and nutritional profile of an ovine Īrish yoghurt drink

Sakshi Hans, MSc

S9. Functional Foods, Nutrition and Health



Bernal Institute

Background & Aims

- Platelet function is linked with thrombosis and cardiovascular disease.
- Foods in the Mediterranean diet (yogurt, fish, olive oil) contain bioactive **polar lipids** (PL) proven to combat inflammation.
- Fermented dairy products have enhanced antithrombotic and anti-inflammatory properties.
- Sheep's milk: Nutrient rich, more digestible, sustainable.



 Assess the effect of ovine yogurt enriched with PL on platelet sensitivity and antithrombotic effect of polar lipid fractions in human plasma.

The effect of ovine milk fermentation on the antithrombotic properties of polar lipids



Ronan Lordan^{a,*}, Aaron M. Walsh^b, Fiona Crispie^{b,c}, Laura Finnegan^b, Paul D. Cotter^{b,c}, Ioannis Zabetakis^{a,*}

- ^a Department of Biological Sciences, University of Limerick, Co. Limerick, Ireland
- b Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland
- ^c Altmentary Pharmabiotic Centre, University College Cork, Co. Cork, Ireland

ARTICLE INFO

Keywords:
Polar lipids
Fermentation
Yoghurt
Inflammation
Antithrombot

ABSTRACT

The effect of fermentation on the antithrombotic properties of polar lipids in ovine milk has been assessed through the production of yoghurts. The total lipids (TL), total neutral lipids (TNL), and total polar lipids (TPL) were extracted. The fatty acid profiles of all yoghurt polar lipids were analysed by GC-MS. The levels of MUFA increased in the fatty acids of the polar lipids, but there was a reduction in PUFA as milk was fermented to yoghurt. The bioactivity of each lipid extract was assessed against platelet-activating factor (PAF) induced platelet aggregation. All yoghurt polar lipids exhibited potent antithrombotic activities with IC₅₀ values ranging from 45 to 77 µg. Shotgun metagenomics determined the species-level microbial composition and functional potential of the yoghurts. Yoghurts containing *L. acidophilus* seem to correlate with greater bioactivity. Several phospholipid biosynthetic genes have been identified in the most antithrombotic yoghurts. This study has demonstrated that fermentation enhances the antithrombotic properties of yoghurt polar lipids against PAF.



PAF and thrombin inhibition by dairy PL

- Platelet-activating factor (PAF) is an inflammatory phospholipid agonist that activates platelets through its GPCR transmembrane receptor (PAF-R).
- Thrombin is a serine protease agonist that binds GPCR receptors PAR1 and PAR4.





Fig. 1 Mechanism of PAF-R activation and PAF-mediated signalling pathway (Harishkumar et. al. 2022)






Fig. 2 Graphical abstract and project overview.

Project overview



Yield of yogurt lipid fractions (Bligh & Dyer method)

Table 1. Yield of the lipid fractions (TL, total lipid; PL, polar lipids; NL, neutral lipids) from raw sheep's milk, skimmed milk-derived placebo drink and full fat yogurt drink (g/100mL). Data is presented as mean \pm SD.

Samples (100 mL)	Total lipids (TL) in grams	Polar lipids (PL) in grams	Neutral lipids (NL) in grams
Raw ovine milk	9.96 ± 0.30 a	0.16 ± 0.01 ^a	8.24 ± 0.23 ^a
Yogurt drink	8.17 ± 0.22^{a}	0.15 ± 0.004 a	7.75 ± 0.19 a
Skimmed milk- derived yogurt drink (Placebo)	0.36 ± 0.01 ^b	0.06 ± 0.002 ^b	0.29 ± 0.01 ^b

 $^{^{}a,b}$, Different superscripts in the same column indicate significant differences among different lipid extracts within the same lipid class (p < 0.05) when means are compared using a Tukey's HSD multiple comparison test.





In vitro bioactivity of ovine yogurt lipid fractions

Table 2. Inhibitory effects (IC₅₀ values) of polar lipids (PL), neutral lipids (NL), and total lipids (TL) isolated from the ovine yogurt drink against human platelet aggregation induced by PAF and TRAP-6 *in vitro*. Data is expressed as mean ± SD.

Food sample	Lipid fraction	IC50 against TRAP-6	IC50 against PAF
		(μ <u>g</u>)	(μg)
Yogurt drink	YPL	313.0 ± 15.0 a	156.7 ± 5.9 a
	YNL	275.4 ± 13.6 b	729.2 ± 35.1 b
	YTL	209.6 ± 10.1 °	248.2 ± 12.0 °
Placebo (skimmed milk-	YPL	45.8 ± 2.1 a	44.0 ± 2.0 a
derived yogurt drink)			
	YNL	47.4 ± 2.1 a	47.2 ± 2.1 a
	YTL	59.2 ± 3.1 a	53.8 ± 2.9 a

a,b,c,d,e Different superscripts in the same column indicate significant differences among different lipid extracts within the same lipid class (p < 0.05) when means are compared using a Tukey's HSD multiple comparison test.



In vitro bioactivity of polar lipid TLC fractions

Table 3. Antiplatelet activity of each PL subclass towards PAF-induced platelet aggregation in PRP, expressed as mean \pm SD.

Yogurt drink polar lipid fractions		EC50 (-) or IC50 aga PAF	ainst IC50 against TRAP-6
		(μ g)	(µg)
1	LPC	-48.1 ± 3.9	348.6 ± 7.9
2	SM	1120 ± 54	250.6 ± 8.3
3	PC	169.5 ± 8.3	205.3 ± 8.9
4	CL	ND	208.0 ± 10.8
5	PE	196.7 ± 6.4	592.1 ± 8.8

Abbreviations: CL, cardiolipin; LPC, lyso-phosphatidylcholine; ND, not determined; PAF, platelet-activating factor; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingomyelin; TRAP-6, thrombin receptor activator peptide 6



Study design: Placebo-controlled crossover trial




Fig. 3 Representation of the placebo-controlled crossover trial study.





Table 4. The effect of yogurt (YD) consumption on platelet activation by TRAP-6, expressed as the Δ EC50 (half-maximal excitatory concentration) at different timepoints.

Treatment group	ΔEC50 day 0-28	ΔEC50 day 42-70	Combined AEC50
YD	17.22 ± 32.2	10.22 ± 33.35	13.72 ± 31.1
PD	7.45 ± 27.5	-5.97 ± 19.95	0.742 ± 23.6








- **Lipid fractions** from ovine yogurt reduce platelet aggregation induced by PAF and TRAP-6.
- Consumption of PL-enriched yogurt reduces platelet aggregation against thrombin pathway (TRAP-6) in interim analysis, in relatively low doses of PL.
- Larger-scale studies required to establish the effect of yogurt intake on platelet activity.
- Intake of such lipid-enriched functional foods could prevent cardiovascular disease linked with systemic inflammation.







Dr Ronan Lordan and Dr Harishkumar Rajendran and Dr Ioannis Zabetakis





University of Limerick, Limerick, V94 T9PX, Ireland. Ollscoil Luimnigh, Luimneach, V94 T9PX, Éire. +353 (0) 61 202020

■ Bernal BioLabs



sakshi.hans@ul.ie

